What are Immunotoxin drugs?

Immunotoxin drugs are pharmacologic agents that share a common mechanism (typically targeting CD25 (IL-2 receptor alpha chain)). 0 are currently marketed, with 4 more in clinical development.

Immunotoxin

0 marketed 3 in Phase 3 1 in Phase 2

This page covers all Immunotoxin drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD25 (IL-2 receptor alpha chain), CD22.

Targets

CD25 (IL-2 receptor alpha chain) · CD22

Phase 3 pipeline (3)

LMB C · Gustave Roussy, Cancer Campus, Grand Paris · Oncology
LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells.
LMB B · Gustave Roussy, Cancer Campus, Grand Paris · Oncology
LMB-B is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells.
DTacP · Changchun BCHT Biotechnology Co. · Oncology
DTacP is a diphtheria toxin-based immunotoxin that targets and eliminates cells expressing specific tumor-associated antigens.

Phase 2 pipeline (1)

Anti-CD22 Immunotoxin · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Oncology
An immunotoxin that binds to CD22 on B-cell lymphomas and delivers a cytotoxic payload to kill malignant cells.